Study of mucus may help guide sinusitis treatmentMar. 29, 2018, 10:20 AM
A patient’s mucus may predict the type of his or her chronic sinusitis, which could help doctors determine whether surgery or medical treatments can produce the best outcomes, according to a recently published Vanderbilt study.
Justin Turner, MD, PhD, associate professor of Otolaryngology-Head and Neck Surgery, the study’s lead author, said it is the first study to use biological markers to identify endotypes of chronic sinusitis in a North American population.
“It’s the first study to do this with mucus,” he added. “We feel like it is pretty unique and a real step forward for the field.”
The study was published online in the Journal of Allergy and Clinical Immunology. Its other authors are Rick Chandra, MD, professor of Otolaryngology; Ping Li, MD; Kimberlee Bonnet, MA and David Schlundt, PhD., associate professor of Psychology.
Chronic sinusitis is a common condition that occurs when the sinuses are swollen for more than three months. The study collected and analyzed the mucus of patients using a minimally invasive method — simply putting a small medical grade sponge into the nostrils. The mucus is analyzed for cytokines, small secreted proteins that allow cells to talk to each other. The cytokine profiles were found to determine six different clusters of chronic sinusitis patients.
“When we look at the postoperative outcomes for those patients, which we assess through a quality of life measure that assesses patient symptom burden, we find that at one year follow up, patients in certain clusters do much better than patients in other clusters,” Turner said.
“In theory, going forward, this is something that could be used in a point-of-care fashion before making a decision to take a patient to surgery. Perhaps some patients may do better with continued medical therapy, or with biologic medications.”
Turner said the findings may pave the way for personalized medicine for chronic sinusitis patients, rather than the type of one-size-fits-all treatment that is the current standard of care. Currently, patients are assessed for how much previous treatment they received and are given prolonged courses of anti-inflammatory medications such as steroids and antibiotics. Only after this are surgical alternatives discussed.
“The problem is that those patients tend to have very different responses to surgery,” he said. The idea behind the study is to identify which patients will have better outcomes ahead of time. “Some patients may be better served with surgery, others with medical treatment,” he said.
Additional research will further define the clusters of patients with the goal of identifying mechanisms that contribute to the development of chronic sinus disease, Turner said.
“Patients who seem clinically similar and undergo sinus surgery reveal a spectrum of eventual outcomes. The ability to potentially target the subset who will benefit from different treatment options would be a major advancement for precision medicine care,” said Ron Eavey, MD, Guy M. Maness Professor and chair of Otolaryngology and director of the Vanderbilt Bill Wilkerson Center. “We are encouraged by Dr. Turner’s exceptional work with his insight to utilize a simple diagnostic source — mucus.”
The study was funded by the National Institutes of Health/National Institute of Deafness and Communication Disorders (award number RO3 DC014809).
Additional support included the National Institutes of Health/National Institute of Allergy and Infectious Diseases (L30 AI113795) and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences.